Indivior Pharmaceuticals, Inc.
Company Stats
- Market Cap
- $4.2B
- as of Sep 30, 2026
- Shares Outstanding
- 118.0M
- Free Float
- 92.4%
Income Statement
- Revenue
- $1.2B
- Operating Income
- $262.0M
- Net Income
- $210.0M
- EBITDA
- $272.0M
- Non-cash Impairment
- $19.0M
- Revenue Growth, 3Y
- 11.2%
- FCF Margin, 3Y Avg
- -11.7%
- FCF Margin, Worst Year
- -28.2%
Cash Flow
- Free Cash Flow
- -$93.0M
- FCF Yield
- -2.2%
- Owner FCF Yield
- -2.8%
Balance Sheet
- Cash & Equivalents
- $195.0M
Returns & Capital
- Share Repurchases
- $11.0M
- Buyback Yield, 3Y Avg
- 1.7%
- SBC, 3Y Avg
- $23.7M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $1.2B | -$93.0M | -7.5% |
| FY2024 | $1.2B | $7.0M | 0.6% |
| FY2023 | $1.1B | -$308.0M | -28.2% |
| FY2022 | $901.0M | -$9.0M | -1.0% |
Annual filing data through FY ended December 31, 2025; shares and float as of November 1, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Earnings
Other Coverage
November 2, 2026
Deals
Indivior Completes All-Stock Merger With Supernus
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
August 14, 2026
Industry Earnings Roundup
Healthcare Earnings: Demand Surges, Costs Bite Back
August 3, 2026
Deals
Indivior to Buy Supernus in All-Stock Merger
August 3, 2026
Deals
Indivior and Supernus to Combine in All-Stock Merger of Equals
June 30, 2026
Share Count Trends
Utilities Lead Quarterly Dilution as Materials Buybacks Gain
Indivior Completes All-Stock Merger With Supernus
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
August 14, 2026
Industry Earnings Roundup
Healthcare Earnings: Demand Surges, Costs Bite Back
August 3, 2026
Deals
Indivior to Buy Supernus in All-Stock Merger
August 3, 2026
Deals
Indivior and Supernus to Combine in All-Stock Merger of Equals
June 30, 2026
Share Count Trends
Utilities Lead Quarterly Dilution as Materials Buybacks Gain